Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: j g cordes who wrote (13459)	1/18/1998 4:33:00 PM
From: John O'Neill	Respond to of 32384

Jim, I appreciate the technical view. We all have good projections for Ligand over the long term, but these technicals can give me insight and provide trading opportunities for parts of my LGND position. Please keep up with the periodic updates, John O

To: j g cordes who wrote (13459)	1/20/1998 6:25:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Jim, My expertise is more in the molecular than financial area. I had predicted that LGND would hit $20 last year. It did set a 52-week high of 18 3/8 in anticipation of the LLY announcement, but fell a bit short. I have predicted that LGND would hit $30 by summer and have another bottle of wine placed on that bet. Lehman Brothers has a $24 target price. I think that LGND's price is being artificially depressed by Farallon, and I don't think that the street really understand's LGND's potential or its underlying technologies. I expect investors who buy LGND at $12 to be all smiles in a rather short time period. The biggest effect of the upcoming clinicals and approvals will be a breaking of LGND's oscillating price chart. I expect the clinicals to generate a steady rise from these very cheap levels.